Suppr超能文献

评估 1 型神经纤维瘤病患者骨骼健康的潜在终点。

Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.

机构信息

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA, USA.

出版信息

Clin Trials. 2024 Feb;21(1):29-39. doi: 10.1177/17407745231201338. Epub 2023 Sep 29.

Abstract

Neurofibromatosis type 1 is a genetic syndrome characterized by a wide variety of tumor and non-tumor manifestations. Bone-related issues, such as scoliosis, tibial dysplasia, and low bone mineral density, are a significant source of morbidity for this population with limited treatment options. Some of the challenges to developing such treatments include the lack of consensus regarding the optimal methods to assess bone health in neurofibromatosis type 1 and limited data regarding the natural history of these manifestations. In this review, the Functional Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration: (1) presents the available techniques for measuring overall bone health and metabolism in persons with neurofibromatosis type 1, (2) reviews data for use of each of these measures in the neurofibromatosis type 1 population, and (3) describes the strengths and limitations for each method as they might be used in clinical trials targeting neurofibromatosis type 1 bone manifestations. The Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration supports the development of a prospective, longitudinal natural history study focusing on the bone-related manifestations and relevant biomarkers of neurofibromatosis type 1. In addition, we suggest that the neurofibromatosis type 1 research community consider adding the less burdensome measurements of bone health as exploratory endpoints in ongoing or planned clinical trials for other neurofibromatosis type 1 manifestations to expand knowledge in the field.

摘要

神经纤维瘤病 1 型是一种遗传综合征,其特征是多种多样的肿瘤和非肿瘤表现。骨骼相关问题,如脊柱侧凸、胫骨发育不良和骨密度降低,是该人群发病率高的一个重要原因,而治疗选择有限。开发此类治疗方法的一些挑战包括缺乏共识,即缺乏评估神经纤维瘤病 1 型患者骨骼健康的最佳方法,以及关于这些表现的自然病史的数据有限。在这篇综述中,神经纤维瘤病和施万细胞瘤国际合作反应评估功能委员会:(1)介绍了用于测量神经纤维瘤病 1 型患者整体骨骼健康和代谢的现有技术,(2)回顾了这些措施在神经纤维瘤病 1 型人群中的应用数据,(3)描述了每种方法的优缺点,因为它们可能用于针对神经纤维瘤病 1 型骨骼表现的临床试验。神经纤维瘤病和施万细胞瘤国际合作反应评估委员会支持制定一项针对神经纤维瘤病 1 型骨骼表现和相关生物标志物的前瞻性、纵向自然史研究。此外,我们建议神经纤维瘤病 1 型研究界考虑将骨骼健康的负担较小的测量值作为正在进行或计划进行的其他神经纤维瘤病 1 型表现的临床试验中的探索性终点,以扩展该领域的知识。

相似文献

4
Neurofibromatosis: part 2--clinical management.神经纤维瘤病:第2部分——临床管理
Arq Neuropsiquiatr. 2015 Jun;73(6):531-43. doi: 10.1590/0004-282X20150042.

本文引用的文献

6
7
MRI-Based Quantitative Osteoporosis Imaging at the Spine and Femur.基于MRI的脊柱和股骨骨质疏松定量成像
J Magn Reson Imaging. 2021 Jul;54(1):12-35. doi: 10.1002/jmri.27260. Epub 2020 Jun 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验